The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
This product has sales of about US$ 20 million in Europe
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
Subscribe To Our Newsletter & Stay Updated
